Decoding how Korean beauty becomes global business.

Hyundai Department Store opens Khōde, a 165 square metre derma beauty shop, on the basement floor of its Pangyo store on 18 September 2026, with around 60 brands and some 250 products aimed at shoppers in their thirties and forties. Olive Young is not absent from this category. It put an Advanced Derma section into 650 of its stores within four months of launching it in March 2026. The category is not what separates them. The format is.

Korea founded the Global Cosmetics Regulatory Authority Summit (GCORAS) to lead regulatory alignment across key export markets like ASEAN, the Middle East, and Latin America. Paired with Korea’s mandatory Safety Assessment regime phasing in from 2028, GCORAS aims to establish mutual recognition for safety dossiers. This turns a domestic compliance burden into a portable global export asset, mitigating fixed compliance costs for indie brands while expanding ODM service roles.

K-Beauty clinical trials have devolved into a profit-driven circus where testing labs unbundle basic device metrics to inflate fees, while subject recycling and data manipulation threaten scientific validity. Domestic brands overspend on superficial device scores, whereas fast-growing brands opt for cost-effective user surveys. Overseas, lax clinical data poses catastrophic legal risks under post-market compliance systems like MoCRA (US) and CPNP (Europe).

On 9 September 2026 APR disclosed an absorption merger with APR Factory, a subsidiary it already owns outright. The merger ratio is 1 to 0. No shares are issued, the contract is dated 16 September and the books close on 31 December. Nothing in the filing moves capital. What moves is the boundary of the company: beauty devices fell from 43% of APR's revenue in 2024 to 18% in the first half of 2026, and APR is absorbing the device plants anyway.

Between 2 and 7 September 2026, MBK Partners put roughly 470 billion won ($349 million) into two Korean beauty assets. One is a control buyout of Skin Idea and Life&Bio at about 300 billion won ($223 million), near eight times combined EBITDA. The other is 172 billion won ($128 million) for 40% of AXIS-Y's parent at a 430 billion won ($320 million) valuation, founder still in control. Korea's largest buyout firm bought the cash and the option at once, and has not decided whic